Core Insights - Cannara Biotech Inc. reported its strongest annual performance in Fiscal 2025, achieving record revenues and significant growth across key financial metrics [3][5][8] - The company increased its national market share by nearly 32% year-over-year, reaching 3.81%, with a notable 53% increase in Quebec, bringing its market share to 12.72% [3][5][20] - Cannara plans to expand its cultivation capacity by approximately 100% over the next four years through the operationalization of additional grow rooms [3][15] Financial Performance - Record net revenues of $107.3 million for Fiscal 2025, a 31% increase from $82.2 million in Fiscal 2024 [5][8] - Adjusted EBITDA rose by 86% to $28.1 million, while net income increased by 103% to $13.1 million [11][24] - Operating cash flow reached $20 million, and free cash flow was $13.7 million for the fiscal year [5][11] Operational Highlights - Gross cannabis revenue before excise taxes increased by 35% to $148.6 million, driven by market penetration and new product offerings [8][11] - The company successfully activated two additional grow zones, increasing total annual production capacity to 39,500 kilograms, achieving its Fiscal 2026 production target ahead of schedule [13][14] - Cannara's disciplined approach to expansion focuses on maintaining margins while enhancing brand recognition across its product lines [14][16] Market Share Expansion - The company’s market share in various provinces showed significant growth, with Manitoba increasing by 342% and Nova Scotia by 860% [20] - Cannara's strategic entry into Quebec's new vape cartridge category with five approved SKUs is expected to further strengthen its market position [16][20] Future Outlook - The company is prioritizing capital investments for a new processing center, supported by a $10 million term loan from BMO, with completion expected by the end of Fiscal 2026 [15][22] - Cannara plans to operationalize three additional grow zones in preparation for future cultivation expansion [15][22]

Core Insights - Cannara Biotech Inc. reported record-breaking financial results for Q3 2025, showcasing significant growth in revenue, gross profit, and cash flow, reflecting the successful execution of its long-term business strategy [3][6][7]. Financial Highlights - Total revenues, net of excise taxes, increased to $27.3 million in Q3 2025, representing a 40% increase year-over-year [7][12]. - Gross profit before fair value adjustments rose to $12.1 million in Q3 2025, a 110% increase from $5.7 million in Q3 2024, with gross margin improving to 44% from 29% [6][12][29]. - Adjusted EBITDA reached a record high of $7.6 million in Q3 2025, a 173% increase compared to the prior year, with an adjusted EBITDA margin of 28% [7][12][29]. - Operating cash flow surged to $13.9 million, up 221% from the previous year, while free cash flow increased to $11.7 million, an 841% rise [7][12][29]. Operational Highlights - The company achieved a 26% yield improvement across its facilities, increasing annual production capacity from 39,500 kg to 50,000 kg, reaching its Fiscal 2026 target a year ahead of schedule [4][15]. - Cannara received acceptance for 5 SKUs for the upcoming launch of the vape category in Québec, representing 20% of all accepted in-store SKUs by the province [4][19]. Market Position - Cannara's gross cannabis revenues before excise taxes increased to $37.8 million in Q3 2025, a 44% increase from $26.2 million in Q3 2024, driven by market penetration and new product introductions [12][29]. - The company maintained a disciplined approach to scaling production, focusing on profitability while expanding its market share across Canada [17]. Debt Management - Cannara successfully reduced its interest rate on its BMO credit facility by 50 basis points, bringing the cost of debt below 6%, reflecting strong financial performance and effective capital management [7][44][45].